Advertisement

Regenerative medicine company Histogenics Corp. of Waltham reported in a journal that its NeoCart tissue implant has shown greater clinical efficacy two years after treatment than microfracture surgery, which is the current standard of care.

SOURCE

Advertisement
Advertisement